Glucuronidation of 3'-azido-3'-deoxythymidine (Zidovudine) by human liver microsomes: Relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid

Carol Braun Trapnell, Raymond W. Klecker, Carlos Jamis-Dow, Jerry M. Collins

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Zidovudine (3'-azido-3'-deoxythymidine [AZT]), an antiviral nucleoside analog effective in the treatment of human immunodeficiency virus infection, is primarily metabolized to an inactive glucuronide form, GAZT, via uridine- 5'-diphospho-glucuronosyltransferase (UGT) enzymes. UGT enzymes exist as different isoforms, each exhibiting substrate specificity. Published clinical studies have shown that atovaquone, fluconazole, methadone, and valproic acid decreased GAZT formation, presumably due to UGT inhibition. The effect of these drugs on AZT glucuronidation was assessed in vitro by using human hepatic microsomes to begin understanding in vitro-in vivo correlations for UGT metabolism. The concentrations of each drug studied were equal to those reported with the usual clinical doses and at concentrations at least 10 times higher than would be expected with these doses. High-performance liquid chromatography was used to assess the respective metabolism and formation of AZT and GAZT. All four drugs exhibited concentration-dependent inhibition of AZT glucuronidation. The respective concentrations of atovaquone and methadone which caused 50% inhibition of GAZT were > 100 and 8 μg/ml, well above their usual clinical concentrations. Fluconazole and valproic acid exhibited 50% inhibition of GAZT at 50 and 100 μg/ml, which are within the clinical ranges of 10 to 100 and 50 to 100 μg/ml, respectively. These data suggest that inhibition of AZT glucuronidation may be more clinically significant with concomitant fluconazole and valproic acid. Factors such as inter- and intraindividual pharmacokinetic variability and changes in AZT intracellular concentrations should be considered as other mechanisms responsible for changes in AZT pharmacokinetics with concomitant therapies.

Original languageEnglish (US)
Pages (from-to)1592-1596
Number of pages5
JournalAntimicrobial agents and chemotherapy
Volume42
Issue number7
StatePublished - Jul 1 1998

Fingerprint

Atovaquone
Zidovudine
Fluconazole
Methadone
Valproic Acid
Liver Microsomes
Glucuronosyltransferase
Uridine
Pharmacokinetics
Pharmaceutical Preparations
Glucuronides
Virus Diseases
Enzymes
Substrate Specificity
Microsomes
Nucleosides
Protein Isoforms
High Pressure Liquid Chromatography
3'-azido-3'-deoxy-5'-O-beta-glucopyranuronosylthymidine
HIV

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

@article{f0a26ab10409410e99795b115513e4aa,
title = "Glucuronidation of 3'-azido-3'-deoxythymidine (Zidovudine) by human liver microsomes: Relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid",
abstract = "Zidovudine (3'-azido-3'-deoxythymidine [AZT]), an antiviral nucleoside analog effective in the treatment of human immunodeficiency virus infection, is primarily metabolized to an inactive glucuronide form, GAZT, via uridine- 5'-diphospho-glucuronosyltransferase (UGT) enzymes. UGT enzymes exist as different isoforms, each exhibiting substrate specificity. Published clinical studies have shown that atovaquone, fluconazole, methadone, and valproic acid decreased GAZT formation, presumably due to UGT inhibition. The effect of these drugs on AZT glucuronidation was assessed in vitro by using human hepatic microsomes to begin understanding in vitro-in vivo correlations for UGT metabolism. The concentrations of each drug studied were equal to those reported with the usual clinical doses and at concentrations at least 10 times higher than would be expected with these doses. High-performance liquid chromatography was used to assess the respective metabolism and formation of AZT and GAZT. All four drugs exhibited concentration-dependent inhibition of AZT glucuronidation. The respective concentrations of atovaquone and methadone which caused 50{\%} inhibition of GAZT were > 100 and 8 μg/ml, well above their usual clinical concentrations. Fluconazole and valproic acid exhibited 50{\%} inhibition of GAZT at 50 and 100 μg/ml, which are within the clinical ranges of 10 to 100 and 50 to 100 μg/ml, respectively. These data suggest that inhibition of AZT glucuronidation may be more clinically significant with concomitant fluconazole and valproic acid. Factors such as inter- and intraindividual pharmacokinetic variability and changes in AZT intracellular concentrations should be considered as other mechanisms responsible for changes in AZT pharmacokinetics with concomitant therapies.",
author = "Trapnell, {Carol Braun} and Klecker, {Raymond W.} and Carlos Jamis-Dow and Collins, {Jerry M.}",
year = "1998",
month = "7",
day = "1",
language = "English (US)",
volume = "42",
pages = "1592--1596",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

Glucuronidation of 3'-azido-3'-deoxythymidine (Zidovudine) by human liver microsomes : Relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. / Trapnell, Carol Braun; Klecker, Raymond W.; Jamis-Dow, Carlos; Collins, Jerry M.

In: Antimicrobial agents and chemotherapy, Vol. 42, No. 7, 01.07.1998, p. 1592-1596.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Glucuronidation of 3'-azido-3'-deoxythymidine (Zidovudine) by human liver microsomes

T2 - Relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid

AU - Trapnell, Carol Braun

AU - Klecker, Raymond W.

AU - Jamis-Dow, Carlos

AU - Collins, Jerry M.

PY - 1998/7/1

Y1 - 1998/7/1

N2 - Zidovudine (3'-azido-3'-deoxythymidine [AZT]), an antiviral nucleoside analog effective in the treatment of human immunodeficiency virus infection, is primarily metabolized to an inactive glucuronide form, GAZT, via uridine- 5'-diphospho-glucuronosyltransferase (UGT) enzymes. UGT enzymes exist as different isoforms, each exhibiting substrate specificity. Published clinical studies have shown that atovaquone, fluconazole, methadone, and valproic acid decreased GAZT formation, presumably due to UGT inhibition. The effect of these drugs on AZT glucuronidation was assessed in vitro by using human hepatic microsomes to begin understanding in vitro-in vivo correlations for UGT metabolism. The concentrations of each drug studied were equal to those reported with the usual clinical doses and at concentrations at least 10 times higher than would be expected with these doses. High-performance liquid chromatography was used to assess the respective metabolism and formation of AZT and GAZT. All four drugs exhibited concentration-dependent inhibition of AZT glucuronidation. The respective concentrations of atovaquone and methadone which caused 50% inhibition of GAZT were > 100 and 8 μg/ml, well above their usual clinical concentrations. Fluconazole and valproic acid exhibited 50% inhibition of GAZT at 50 and 100 μg/ml, which are within the clinical ranges of 10 to 100 and 50 to 100 μg/ml, respectively. These data suggest that inhibition of AZT glucuronidation may be more clinically significant with concomitant fluconazole and valproic acid. Factors such as inter- and intraindividual pharmacokinetic variability and changes in AZT intracellular concentrations should be considered as other mechanisms responsible for changes in AZT pharmacokinetics with concomitant therapies.

AB - Zidovudine (3'-azido-3'-deoxythymidine [AZT]), an antiviral nucleoside analog effective in the treatment of human immunodeficiency virus infection, is primarily metabolized to an inactive glucuronide form, GAZT, via uridine- 5'-diphospho-glucuronosyltransferase (UGT) enzymes. UGT enzymes exist as different isoforms, each exhibiting substrate specificity. Published clinical studies have shown that atovaquone, fluconazole, methadone, and valproic acid decreased GAZT formation, presumably due to UGT inhibition. The effect of these drugs on AZT glucuronidation was assessed in vitro by using human hepatic microsomes to begin understanding in vitro-in vivo correlations for UGT metabolism. The concentrations of each drug studied were equal to those reported with the usual clinical doses and at concentrations at least 10 times higher than would be expected with these doses. High-performance liquid chromatography was used to assess the respective metabolism and formation of AZT and GAZT. All four drugs exhibited concentration-dependent inhibition of AZT glucuronidation. The respective concentrations of atovaquone and methadone which caused 50% inhibition of GAZT were > 100 and 8 μg/ml, well above their usual clinical concentrations. Fluconazole and valproic acid exhibited 50% inhibition of GAZT at 50 and 100 μg/ml, which are within the clinical ranges of 10 to 100 and 50 to 100 μg/ml, respectively. These data suggest that inhibition of AZT glucuronidation may be more clinically significant with concomitant fluconazole and valproic acid. Factors such as inter- and intraindividual pharmacokinetic variability and changes in AZT intracellular concentrations should be considered as other mechanisms responsible for changes in AZT pharmacokinetics with concomitant therapies.

UR - http://www.scopus.com/inward/record.url?scp=0031808472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031808472&partnerID=8YFLogxK

M3 - Article

C2 - 9660989

AN - SCOPUS:0031808472

VL - 42

SP - 1592

EP - 1596

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -